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Abstract: Some alkyl and aryl derivatives of 9H-purine-6-thiol were synthe-
sized and evaluated in vitro and in vivo for potential antithyroid effects. Spec-
trophotometric studies demonstrated 1:1 charge transfer complexation between 
iodine and these compounds with quite high values of the formation constants. 
The blood assays of rats treated with these compounds revealed significant an-
tithyroid activity for almost all the compounds, which was further supported by 
a histological study of the thyroid tissues of the animals. These compounds are 
expected to provide less toxic alternative of the existing medicines as the sul-
fanyl group, which is known to be a cause of toxicity of many drugs, is blocked 
by alkyl/aryl substituents. 
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INTRODUCTION 
Hyperthyroidism is a major dysfunction of the thyroid gland in which the 
gland produces more hormones than is normally required by the body for its nor-
mal metabolic functions as well as mental and physical growth. Thyroid disorder 
disturbs not only other glands of endocrine system, but also other organs since 
they act on nearly every cell in the body.1 The available treatments for hyper-
active thyroid are: thyroidectomy (surgical removal of a part of or the whole 
gland), radioactive iodine therapy and antithyroid drugs. The former two modes 
provide permanent treatment but have serious drawbacks. The side effects of 
radioiodine are the development of tumors, leukemia, thyroid cancer and birth 
defects in women but the reported incidences are low.2 On the other hand, sur-
gery may lead to tracheal compression due to bleeding, infection, bilateral vocal 
fold paralysis and superior laryngeal nerve damage. Perpetual hypothyroidism is 
common for both these treatments.3,4 Moreover, certain hyperthyroid conditions 
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are not permanent and do not need surgery or radioiodine therapy. The use of 
antithyroid drug becomes the only choice under such conditions but there is a 
scarcity of drugs in this particular area. Propylthiouracil, methimazole (MMI) 
and carbimazole are the only widely used synthetic antithyroid agents (SATs).5 
These drugs have many serious side-effects, such as agranulocytosis, liver da-
mage, aplastic anemia and vasculitis, while minor side-effects, such as itching, 
rash, hives, pain and swelling in joints, fever, change in taste, nausea and vo-
miting have been observed in fifteen percent of the patients treated with these 
drugs.6–8 The presence of free SH group in these drugs is reported to be the cause 
of the toxic side effects, as with many other compounds containing the sulfon-
amide group.9 For this reason, an earnest need was felt to search for new, less 
toxic and more effective SATs. Many compounds were evaluated and some were 
reported to possess recognizable antithyroid activity.5,10 SATs are supposed to 
act either through inhibition of the thyroperoxidase enzyme or by making stable 
charge transfer (CT) complexes with iodine in which iodine acts as a σ-acceptor 
and the synthetic compound as an n-donor.11 Although, many drugs, such as 
levamisole, tetramethylthiourea, tetrahydrozoline and phenothiazines, have no ef-
fect on peroxidase yet exhibit strong antithyroid activity in vivo due to complex-
ation with iodine.12 Studies of CT complexation of various drugs having a thia-
zole or imidazole ring with iodine using UV/visible spectroscopy revealed a posi-
tive correlation between the formation constant (Kc) and in vivo antithyroid acti-
vity. Compounds having Kc ≥ 100 L mol–1 were found to exhibit recognizable 
antithyroid activity.13 MMI acts predominantly through CT complexation with a 
Kc value of 23193 L mol–1.14 Heterocyclic compounds, including purines, form 
CT complexes with iodine.15–17 Similarly, the medicinal value of certain purines 
and purine derivatives, including 6-mercaptopurine (6MP, 9H-purine-6-thiol); 
against HIV-1, cancer, bacteria and miscellaneous microbes was also reported.18–21 
In light of the above, it was proposed to derivatize 6MP and to evaluate the an-
tithyroid potential of the formed compounds. These compounds were expected to 
form stable CT complexes with iodine, like other heterocyclic compounds, which 
is a clue to antithyroid activity. Moreover, the suspected toxic effects due to free 
–SH group were ruled out by blocking this site with alkyl substituents. This also 
led to 1:1 complexation as the only site for an n–σ complex was available at the 
N-9 position. 
EXPERIMENTAL 
Materials, instruments and methods 
Iodine (suprapur, bisublimed) was obtained from Merck and kept in dark in a dessicator 
containing P2O5. Dimethyl sulfoxide (DMSO) of spectroscopic grade was obtained from Merck. 
It was dried over calcium hydride, distilled under reduced pressure and stored over type 4Å 
molecular sieves. 9H-Purine-6-thiol monohydrate (6MP) was obtained from Sigma-Aldrich 
and was used without further purification. 1-Methyl-1H-imidazole-2-thiol (MMI, methima-
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zole) of analytical grade was purchased from Sigma-Aldrich and used without further purify-
cation for the in vivo study. Free T3 and T4 kits of Immunotech (France) and rat-TSH ELISA 
kit from Cusabio Biotech Co. Ltd. were used. 
The spectra were recorded on a double beam UVD-3500 spectrophotometer (Labomed 
Inc.) and the slides of thyroid tissues were studied under an Olympus BX51microscope fitted 
with an Olympus DP12 digital camera. The melting points were determined on a Gallenkamp 
melting point apparatus and are uncorrected. The 1H-NMR and 13C-NMR were determined in 
DMSO-d6 using TMS as the internal standard on a Bruker Avance 300 (300 MHz for 1H- and 
75 MHz for 13C-NMR). The mass spectra were recorded on a Bruker Esquire 300+ ion trap 
with ESI ionization. Microanalysis for carbon, hydrogen and nitrogen was realized on a Per-
kin Elmer 2400-CHN analyzer. 
Synthesis of 9H-purine-6-thiol derivatives  
9H-Purine-6-thiol monohydrate (0.170 g, 1 mmol) in aqueous sodium hydroxide (2 M, 
10 mL) was stirred at room temperature with the respective alkyl halides (1 mmol). The clear 
solution was stirred until the insoluble alkyl halides disappeared. After completion of the re-
action, the pH of the solution was adjusted to 5.0 by the addition of glacial acetic acid and the 
white precipitates were filtered and recrystallized. All the compounds (Fig. 1) were synthe-
sized using literature methods,22–25 except for (9) which was not found in the literature.  
N
N
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Fig. 1. General structure of the 9H-purine-6-thiol derivatives (R: 1, CH3; 2, 
C2H5; 3, C3H7; 4, C4H9; 5, C5H11; 6, C6H13; 7, C7H15; 8, C8H17; 9, C9H19; 
10, C10H21; 11, PhCH2. 
Assessment of antithyroid activity 
In vitro. The in vitro activity was assessed by studying spectrophotometrically the com-
plexation of the compounds with iodine. Solutions of iodine and the compounds were pre-
pared just before the start of the experiment by diluting accurately prepared stock solutions in 
DMSO. The iodine concentration was kept constant (2×10–5 M), while those of the com-
pounds were varied between 1×10–4 M and 1×10–3 M. The reactions were performed directly 
in the spectrophotometric cell by mixing 1.5 mL of the compound solutions and iodine so-
lution and the spectra were recorded immediately. New absorption bands appeared which de-
monstrated the formation of CT complexes between iodine and the compound(s). The stoi-
chiometry of the complex was ascertained by the method of continuous variations.26 
In vivo. The in vivo study was performed on young male Wistar rats of 175±25 g weight. 
The animals were divided into fifteen groups, i.e., the control, the vehicle control (solvent 
treated), the MMI treated and twelve groups for the compounds under study (6MP and 1–11). 
MMI was used as a positive control, so that the efficacy of the potential compounds could also 
be compared with the most popular existing drug. Five animals were allocated to each group 
and were fed chick feed with water ad libitum. Solutions of the compounds and MMI in 
DMSO were administered via i.p. injection to the respective groups at a dose rate of 20 mg kg-1 
per animal daily in the morning for 15 days. The control and vehicle control categories re-
ceived an equivalent dose of normal saline and the solvent, respectively, for the same dura-
tion. On the 16th day, the animals were weighed and carried to the dissection room for blood 
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sampling and dissection. Due time was allowed before blood sampling to avoid hormonal 
changes because of any stress caused by transportation. Blood samples were collected from all 
the animals by puncturing the abdominal aorta under light diethyl ether anesthesia. Standard 
animal protocols were adopted for the experimentation.27 Free T3 and T4 levels were deter-
mined using radioimmunoassay technique, while that of TSH by the ELISA method. The ani-
mals were subsequently sacrificed on the same day under deep diethyl ether anesthesia and the 
thyroid was removed, washed and weighed. Sections of the gland were fixed in 4 % paraform-
aldehyde (PFA) solution for 4–6 h and stained with hematoxylin and eosin to prepare slides for 
histological studies. 
RESULTS AND DISCUSSION 
All the compounds (Fig. 1) were synthesized using literature methods except 
9, which is not known to be reported. Previously, confirmation of the structures 
of the known compounds was established using melting point and elemental ana-
lysis only. Complete spectral information, including mass spectrometry, 1H-NMR, 
13C-NMR and CHN, were determined in the present study for detailed structure 
elucidation. The results are given in the Supplementary material. 
All compounds absorbed in the UV region between 280 and 330 nm. The 
compounds  1–11 exhibited 1:1 complexation with iodine. 6MP also showed 
complexation but not of 1:1 stoichiometry. The compounds were soluble only in 
DMSO, therefore, its use as a solvent was inevitable, apart from its interaction 
with I2, like many other aromatic and alkyl halide solvents.28 A solution of iodi-
ne in DMSO gave sharp peaks at 295 and 365 nm, which are characteristic of the 
I3–.29 Occasionally other peaks around 250–255 nm were also observed. The in-
teraction of DMSO with iodine is a slow process resulting in a weak com-
plex.30,31 It was observed that in the presence of strong n-donors, its interaction 
with I2 becomes very restrained. The CT band generally appears at 265–270 nm. 
The reaction mixture exhibited negligible absorption for the compound at con-
centrations below 2×10–4 M. On increasing the concentration of compounds 
(≥ 3×10–4 M), two peaks appeared usually at 300 and 270 nm, the latter being 
characteristic of complex formation. 
The formation constants and molar extinction coefficients of the complexes 
were determined using the Lang method.32 This method derives a mathematical 
expression to calculate Kc for 1:1 stiochiometric complexes: 
 K c = [C]/([I0]–[C])([P0]–[C]) (1) 
where, [I0] and [P0] are the initial concentrations of iodine and the compound(s), 
respectively, whilst [C] is the concentration of the complex. Now, according to 
Beer–Lambert Law: 
 [C]  =  εcdc 
where dc and εc are the absorbance and extinction coefficient of the complex, 
respectively. The value of dc was calculated by subtracting the absorbance due to 
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free iodine present in the mixture from the observed absorbance of the reaction 
mixture. The solution of pure compound of same concentration is kept in the 
reference cell of the spectrophotometer. Now Eq. (1) can be re-written in the 
form: 
 Y  = (1/εc)·X + 1/(Kcεc)  (2) 
where Y = [I0][P0]/dc and X = [I0] + [P0] – dc/εc 
Equation (2) is an equation of a straight line with slope 1/εc and Y-intercept 
1/(Kcεc). First, the equation was solved using an assumed value of εc. This gave 
not only a value for Kc, but also a new value of εc was obtained. This new value 
differed from the old assumed value of εc. Now, the new value of εc was used to 
solve the equation and so forth until both εc and Kc converged to discrete values 
(Table I). This is a lengthy process and was performed by developing a com-
puter-based iterative algorithm, which not only calculated the εc and Kc values, 
but also the values of X and Y. A linear regression curve gave the best fit for the 
XY scatter (R2 > 0.99), thus confirming 1:1 complexation between iodine and the 
compounds 1–11. 
TABLE I. Spectrophotometric properties of the CT complexes of the studied compounds with I2 
Compound  CTB
a / nm  Kc / 10
4 L mol
-1  εc
b / 10
5 L mol
-1 cm
-1 
1  265 1.031  0.552 
2  270 0.250  1.52 
3  315 0.458  1.301 
4  265–70 0.562  1.129 
5  315 0.642  1.205 
6  265–70 0.279  1.121 
7  265–70 0.479  0.876 
8  265–270 0.256  1.255 
9  265–70 0.536  1.0452 
10  265–70 0.962  0.635 
11  265–70 2.335  0.794 
aCharge transfer band; bmolar extinction coefficient 
The antithyroid effects of potential compounds can be ascertained in vivo by 
a decrease in the thyroid hormones, which is further confirmed by a correspond-
ing increase in the pituitary hormone (TSH) levels. Similarly, regular exposure to 
SATs is known to increase the thyroid weight and change the thyroid histology.33 
In the present study, due consideration was given to all these aspects. 
The radioimmunoassay results showed a decrease of free T3 and T4 levels in 
the serum of the treated groups, as compared to the control and vehicle control 
animals. In addition, a relative increase was observed in the TSH levels for the 
treated groups (Table II), which is a clear sign of the antithyroid potential of the 
studied compounds. 
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The hormonal variations were quite explicit, yet the data was analyzed 
statistically using the Dunnett test to further validate the results. This is a popular 
and useful hypothesis testing method used for comparing the treatments with a 
control when the sample size is the same in the control and the treatments. The 
Dunnett D value is: 
 D  = dα(k,ν)(2Sw2/n)1/2 
where, dα(k,ν) is the critical Dunnett value at a given significance level (α), the 
number of non-control treatments (k) and the degree of freedom (ν); n is the 
sample size and Sw2 is the combined estimate of the common variance.34 
TABLE II. Hormonal variations observed after 15 day dose administration (n = 5, dose rate =  
= 20 mg kg-1) 
Animal group 
Mean hormone levels 
FT3 / pmol L
-1  FT4 / pmol L
-1  TSH / μ i.u. mL
-1 
Control 8.41
a±0.64
b 35.86±2.14 1.64±0.32 
Vehicle control  8.15±0.81 34.09±1.67  1.70±0.23 
Treatment
c 
6MP  5.86±0.33 24.49±2.48  2.99±0.27 
1  5.01±0.65 24.32±2.31  2.93±0.45 
2  6.78±0.90 26.66±2.82  2.40±0.58 
3  6.01±0.97 25.92±2.23  2.59±0.71 
4  5.82±0.92 26.67±2.34  2.62±0.34 
5  5.88±0.71 25.16±3.26  2.68±0.39 
6  6.69±0.81 26.96±2.58  2.40±0.56 
7  5.90±0.93 26.77±2.39  2.56±0.38 
8  6.79±0.85 27.50±2.40  2.38±0.56 
9  5.89±1.17 26.99±2.14  2.40±0.26 
10  5.37±0.97 25.00±2.08  2.88±0.25 
11  3.33±1.05 16.08±2.00  3.38±0.30 
MMI  3.36±0.96 17.28±1.98  3.53±0.39 
aMean values of assay results run in duplicate; bstandard deviation; cp ≤ 0.05 (with respect to the vehicle control) 
The research hypotheses were: 
Ha: μi < μc; will be true if (yi – yc) ≤ –D (for comparison of the FT3 and FT4 
levels) and Hb: μi > μc; will be true if (yi – yc) ≥ D (for comparison of the TSH 
levels). Here, i and c stand for the treatment sample and the control, while μ and 
y for the population and sample means, respectively. 
The hormone levels for all the treatments were compared with the controls 
using this method at α = 0.05. The test results confirmed the efficacy of the com-
pounds in lowering the serum free T3 and T4 levels with a corresponding simul-
taneous increase in the TSH levels. This clearly demonstrates the antithyroid po-
tential of these compounds. However, 11 was proved to be the most potent among 
the whole series. It exhibited antithyroid potential almost equivalent to MMI.  
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Comparison between the Kc values and the pertaining hormonal variations 
revealed a positive correlation between Kc and the in vivo antithyroid activity. 
The relationship was observed to be fairly linear for moderate values of Kc. All 
the compounds demonstrated in vivo antithyroid effects; the higher activity of 11 
can be attributed to resonance, which resulted in a more stable equilibrium, 
evident from the high Kc value of the 11:I2 complex.  
SATs are known to increase in the weight of the thyroid gland. Since thyroid 
weight also depends on the size of the animal, a useful index called “thyroid 
body index” (TBI) was introduced to account for the effect of body weight on the 
thyroid weight. TBI can be defined as the weight of clean thyroid tissues (mg) per 
100 g of body weight. These indices for treated animals were found to be higher 
than those of the controls (Table III). Moreover; the TBI values, like those of Kc, 
were also found proportional to the change in hormone levels. This depicts that 
the TBI can also be used as an empirical parameter for the assessment of anti-
thyroid activity. Sections from thyroids of the treated animals showed marked 
difference in the shape of the glandular cells and quantity of intracellular fluid 
(colloid). Follicular cell hyperplasia and hypertrophy of various degrees were 
also observed in the treated animals (Table III). 
Table III. Histological observations of the thyroid tissues from different animal groups (±: 
slight; +: mild; ++: moderate; +++: severe) 
Animal group/description  Follicular cell 
hypertrophy/hyperplasia  Colloid depletion TBI×100 / mg g
-1 
Control Nil  Nil  5.21 
Vehicle control  ±  + 6.01 
6MP ++  ++  10.35 
1  +++ +++  11.23 
2  + ++  7.41 
3  ++ ++  7.83 
4  ++ ++  9.26 
5  + ++  8.61 
6  + ++  7.37 
7  ++ ++  8.79 
8  + ++  7.03 
9  ++ ++  7.58 
10  ++ +++  11.26 
11  +++ +++  14.27 
MMI +++  +++  16.11 
The thyroid of the control and vehicle control animals showed a cuboidal 
follicular epithelium with ample quantities of colloid. On the other hand, severe 
colloid depletion with a semi-cylindrical to cylindrical-shaped epithelium was 
observed for the treated animals (Fig. 2). Very slight atrophy was noted in the 
follicular cells, which demonstrates the smaller toxicity of these compounds. 
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Obesity in the treated animals was also seen in the second week of treatment, 
without any sign of intoxication because eating and drinking habits remained 
normal. No animal died during the study period. 
        
 (A)  (B) 
Fig. 2. Microscopic view of thyroid sections: А) control with epithelium full of colloid and 
normal nuclei of follicular cells, B) 11-treated animal, severe colloid depletion 
is visible with follicular cell hypertrophy and hyperplasia. 
CONCLUSIONS 
The studied derivatives of 9H-purine-6-thiol form 1:1 charge transfer com-
plexes with iodine and were found to possess highly significant antithyroid acti-
vity in vivo, which was in good correlation with the Kc values. 6-(Benzylsulfa-
nyl)-9H-purine showed the maximum antithyroid effects, comparable to that of 
methimazole and may have less side effects due to the blockage of the free SH 
group. Further research on these compounds could lead to the discovery of new 
drugs. 
SUPPLEMENTARY MATERIAL 
Аnalytical and spectral data of synthesized compounds are available electronically from 
http://www.shd.org.rs/JSCS/, or from the corresponding author on request. 
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ИЗВОД 
АНТИТИРОИДНА АКТИВНОСТ 6-(АЛКИЛСУЛФАНИЛ)-9Н-ПУРИНА 
ISMAT FATIMA
1, MUNAWAR A. MUNAWAR
1, AFFIA TASNEEM
2, SARWAT JAHAN
3, 
MISBAHUL A. KHAN
1 и SHAKEEL AHMED
3 
1Institute of Chemistry, University of the Punjab-Lahore, 
2 CENUM, Mayo Hospital – Lahore и 
3Department of Animal Sciences, Quid-i-Azam University Islamabad, Pakistan 
Синтетисани су алкил и арил деривати 9Н-пурин-6-тиола и испитивана је њихова in vit-
ro и in vivo антитироидна активност. Спектрофотометријска анализа је показала да се ства-
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рају комплекси између јода и ових једињења у односу 1:1, уз високу константу асоцијације. 
Анализа крви пацова третираних овим једињењима је показала да сва једињења имају зна-
чајну антитироидну активност, што је даље потврђено хистолошким налазима тироидног 
ткива. Могућа предност ових једињења у односу на постојеће антитироидне лекове је у сма-
њеној  токсичности,  пошто  је  сулфанил  група,  иначе  позната  као  узрочник  токсичности 
многих лекова, блокирана алкил/арил супституентима. 
(Примљено 13. децембра 2010, ревидирано 4. фебруара 2011) 
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